Last Updated | 31 March 2026

LIGHTBEAM 01A MK-9999-01A

LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in paediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors
External Registry
Site Status Queensland Children's Hospital Sydney Children's Hospital Royal Children's Hospital
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Relapsed/Refractory
National Sponsor Merck Sharp & Dohme LLC
Open Date N/A
Conditions B-cell Acute Lymphoblastic Leukemia
Diffuse Large B-cell Lymphoma
Burkitt Lymphoma
Neuroblastoma
Ewing Sarcoma
Patient Range 6 months25 years
Disease Type Leukaemia / Lymphoma / Blood Disorders, Neuroblastoma and Ganglioneuroblastoma, Soft Tissue and Bone Tumours (Sarcoma)
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.